Thu, Jul 24, 2014, 8:24 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Alnylam Pharmaceuticals, Inc. Message Board

  • thirdmeinvestor thirdmeinvestor Apr 12, 2014 6:33 PM Flag

    Short term and Q4 catalysts

    For the short term, Alnylam is delivering two Plenary oral presentations and one poster on April 30:
    Patisiran; International Symposium on Amyloidosis (ISA), April 27 - May 1. One Plenary paper further analyzes Phase 2 data of Patisiran.

    Pending acceptance, more papers will be presented in the following meetings.
    ALN-PCSsc; Arteriosclerosis, Thrombosis, and Vascular Biology, May 1 - 3
    ALN-AAT; Digestive Disease Week, May 4 - 6
    ALN-AT3; World Federation on Hemophilia, May 11 - 14
    ALNY 5X15; TIDES, May 12 - 15
    ALN-CC5; International Conference on Complement Therapeutics, June 6 - 11

    For the time frame of October – December, look up my post of March 29: [[ When the data from ALN-AT3 for hemophilia A and B, -TTR02 for FAP, and -TTRsc for FAC come out, the share price could triple from here.]]

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ALNY
55.76-0.10(-0.18%)Jul 24 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Amazon.com Inc.
NasdaqGSThu, Jul 24, 2014 4:00 PM EDT
Atlatsa Resources Corporation
NYSE MKTThu, Jul 24, 2014 4:00 PM EDT
Puma Biotechnology, Inc.
NYSEThu, Jul 24, 2014 4:02 PM EDT